These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3109063)

  • 1. Characteristics of a heat treated antihaemophilic cryoprecipitate.
    Skjønsberg OH; Gravem K; Kierulf P; Godal HC
    Thromb Res; 1987 Mar; 45(5):625-34. PubMed ID: 3109063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
    Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
    J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of pH on heat denaturation of anti-haemophilic cryoprecipitate.
    Skjønsberg OH; Gravem K; Kierulf P; Vaeret A; Godal HC
    Thromb Res; 1987 Jul; 47(2):183-90. PubMed ID: 3116715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
    Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
    Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin generation during production of freeze dried antihaemophilic cryoprecipitate.
    Skjønsberg OH; Kierulf P; Gravem K; Heistø H; Godal HC
    Thromb Res; 1986 Feb; 41(3):405-14. PubMed ID: 3085272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification of the factor VIII complex.
    Thorell L; Blombäck B
    Thromb Res; 1984 Aug; 35(4):431-50. PubMed ID: 6435279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
    Tuddenham EG; Lane RS; Rotblat F; Johnson AJ; Snape TJ; Middleton S; Kernoff PB
    Br J Haematol; 1982 Oct; 52(2):259-67. PubMed ID: 6812613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of fresh-frozen plasma and cryoprecipitate in dogs with von Willebrand's disease or hemophilia A.
    Stokol T; Parry B
    J Vet Intern Med; 1998; 12(2):84-92. PubMed ID: 9560764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of the factor VIII protein and Factor XIII in various factor VIII concentrates.
    Nilsson IM; Holmberg L; Stenberg P; Henriksson P
    Scand J Haematol; 1980 Apr; 24(4):340-9. PubMed ID: 6774412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
    Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gel filtration patterns of factor VIII coagulant antigen and factor VIII related antigen in normal and von Willebrand's disease.
    Chediak J; Peake I; Bloom A
    Thromb Haemost; 1983 Aug; 50(2):509-12. PubMed ID: 6415844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of molecular size of factor VIII/von Willebrand factor in von Willbrand's disease.
    Mikami S; Takahashi Y; Nishino M; Okubo Y; Fukui H
    Thromb Haemost; 1981 Jun; 45(3):272-5. PubMed ID: 6792740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with factor VIII: C inhibitors and acquired von Willebrand's disease in an adult at Ramathibodi Hospital.
    Angchaisuksiri P; Atichartakarn V; Pathepchotiwong K; Jootar S; Ungkanont A; Chuncharunee S
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():152-8. PubMed ID: 7886560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
    Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
    Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic dysfunction in patients with classic hemophilia receiving lyophilized factor VIII concentrates and cryoprecipitate.
    Tsoukas C; Gervais F; Fuks A; Guttmann RD; Strawczynski H; Shuster J; Gold P
    Can Med Assoc J; 1983 Oct; 129(7):713-7. PubMed ID: 6225504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryoprecipitate transfusion in variant von Willebrand's disease and thrombocytopenia.
    Krizek DM; Rick ME; Williams SB; Gralnick HR
    Ann Intern Med; 1983 Apr; 98(4):484-6. PubMed ID: 6404206
    [No Abstract]   [Full Text] [Related]  

  • 18. Specific factor VIII-related antigen fragmentation: an in vivo and in vitro phenomenon.
    Montgomery RR; Johnson J
    Blood; 1982 Oct; 60(4):930-9. PubMed ID: 6180785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lyophilized cryoprecipitate for children with hemophilia A.
    Nuchprayoon I; Sahasittiwat S; Kittikalayawong A; Chantanakajornfung A
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S293-7. PubMed ID: 12188426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
    McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
    Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.